Entero Therapeutics (Entero Therapeutics) Cash-to-Debt : 0.49 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Entero Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Entero Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.49.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Entero Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Entero Therapeutics's Cash-to-Debt or its related term are showing as below:

ENTO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 3.78 Max: No Debt
Current: 0.49

During the past 10 years, Entero Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 3.78.

ENTO's Cash-to-Debt is ranked worse than
85.13% of 1527 companies
in the Biotechnology industry
Industry Median: 6.23 vs ENTO: 0.49

Entero Therapeutics Cash-to-Debt Historical Data

The historical data trend for Entero Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Entero Therapeutics Cash-to-Debt Chart

Entero Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.11

9.64

8.01

1.54

4.49

Entero Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															3.20	3.08	14.25	4.49	0.49

Competitive Comparison of Entero Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Entero Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entero Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entero Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Entero Therapeutics's Cash-to-Debt falls into.

Entero Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Entero Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.712	/	(0.68	+	0.147)
	=	4.49

Entero Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.432	/	(0.458	+	6.525)
	=	0.49

Entero Therapeutics (NAS:ENTO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Entero Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Entero Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Entero Therapeutics (Entero Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (NAS:ENTO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431

Website

https://www.firstwavebio.com

First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Executives

James Sapirstein	director, officer: President and CEO	1517 SAN JACINTO, HOUSTON TX 77002
Sarah Romano	officer: Chief Financial Officer	271 WAVERLY OAKS ROAD, WALTHAM MA 02452
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
David Andrew Hoffman	director	777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431
Edward Borkowski	director	1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Alastair Riddell	director	C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226
Vern Lee Schramm	director	1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461
Gregory Oakes	director	760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
James Pennington	officer: CHIEF MEDICAL OFFICER	25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Daniel H Schneiderman	officer: CHIEF FINANCIAL OFFICER	760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Ross Edmund Burke Jr.	10 percent owner	C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196
Johan M. Spoor	director, officer: President and CEO	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Maged Shenouda	director	305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Pelican Partners Llc	10 percent owner	PO BOX 2422, WESTPORT CT 06880